M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout BioPharma DiveThe deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.M&A / DealsNeuroscienceRead full story pharminent March 31, 2026 (Last updated: April 1, 2026) BioPharma Dive The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis BuyNext: Novo hits back at rivals with cut-price Wegovy subscriptions Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
